|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TFPI |
Gene summary for TFPI |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TFPI | Gene ID | 7035 |
| Gene name | tissue factor pathway inhibitor | |
| Gene Alias | EPI | |
| Cytomap | 2q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | P10646 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7035 | TFPI | AEH-subject2 | Human | Endometrium | AEH | 2.29e-05 | -9.00e-02 | -0.2525 |
| 7035 | TFPI | AEH-subject3 | Human | Endometrium | AEH | 1.70e-04 | -1.45e-01 | -0.2576 |
| 7035 | TFPI | AEH-subject4 | Human | Endometrium | AEH | 3.62e-02 | -3.74e-02 | -0.2657 |
| 7035 | TFPI | EEC-subject1 | Human | Endometrium | EEC | 4.70e-07 | -1.47e-01 | -0.2682 |
| 7035 | TFPI | EEC-subject2 | Human | Endometrium | EEC | 3.89e-10 | -1.56e-01 | -0.2607 |
| 7035 | TFPI | EEC-subject3 | Human | Endometrium | EEC | 5.38e-05 | -3.19e-02 | -0.2525 |
| 7035 | TFPI | EEC-subject5 | Human | Endometrium | EEC | 7.78e-06 | -1.41e-01 | -0.249 |
| 7035 | TFPI | GSM5276934 | Human | Endometrium | EEC | 1.00e-18 | 5.41e-01 | -0.0913 |
| 7035 | TFPI | GSM5276935 | Human | Endometrium | EEC | 4.30e-04 | -1.30e-01 | -0.123 |
| 7035 | TFPI | GSM5276937 | Human | Endometrium | EEC | 2.01e-19 | 5.60e-01 | -0.0897 |
| 7035 | TFPI | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 6.41e-05 | -1.42e-01 | -0.1869 |
| 7035 | TFPI | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 9.87e-05 | -1.56e-01 | -0.1875 |
| 7035 | TFPI | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 6.46e-06 | -1.56e-01 | -0.1883 |
| 7035 | TFPI | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 8.71e-07 | -1.56e-01 | -0.1934 |
| 7035 | TFPI | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.89e-07 | -1.56e-01 | -0.1917 |
| 7035 | TFPI | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.91e-09 | -1.12e-01 | -0.1916 |
| 7035 | TFPI | LZE2T | Human | Esophagus | ESCC | 4.49e-03 | 3.59e-01 | 0.082 |
| 7035 | TFPI | LZE8T | Human | Esophagus | ESCC | 3.38e-17 | 9.25e-01 | 0.067 |
| 7035 | TFPI | P4T-E | Human | Esophagus | ESCC | 3.84e-21 | 9.49e-01 | 0.1323 |
| 7035 | TFPI | P8T-E | Human | Esophagus | ESCC | 1.72e-16 | 5.06e-01 | 0.0889 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00714984 | Prostate | BPH | cellular response to fluid shear stress | 9/3107 | 21/18723 | 4.10e-03 | 2.03e-02 | 9 |
| GO:00344052 | Prostate | BPH | response to fluid shear stress | 12/3107 | 35/18723 | 8.36e-03 | 3.61e-02 | 12 |
| GO:005254719 | Prostate | Tumor | regulation of peptidase activity | 137/3246 | 461/18723 | 2.48e-11 | 1.71e-09 | 137 |
| GO:004206019 | Prostate | Tumor | wound healing | 127/3246 | 422/18723 | 5.32e-11 | 3.41e-09 | 127 |
| GO:005254819 | Prostate | Tumor | regulation of endopeptidase activity | 126/3246 | 432/18723 | 5.86e-10 | 3.01e-08 | 126 |
| GO:004586119 | Prostate | Tumor | negative regulation of proteolysis | 102/3246 | 351/18723 | 3.09e-08 | 9.94e-07 | 102 |
| GO:005134617 | Prostate | Tumor | negative regulation of hydrolase activity | 97/3246 | 379/18723 | 2.87e-05 | 3.46e-04 | 97 |
| GO:001095116 | Prostate | Tumor | negative regulation of endopeptidase activity | 68/3246 | 252/18723 | 7.91e-05 | 8.19e-04 | 68 |
| GO:001046617 | Prostate | Tumor | negative regulation of peptidase activity | 70/3246 | 262/18723 | 8.76e-05 | 8.66e-04 | 70 |
| GO:005087818 | Prostate | Tumor | regulation of body fluid levels | 91/3246 | 379/18723 | 5.37e-04 | 3.91e-03 | 91 |
| GO:000759614 | Prostate | Tumor | blood coagulation | 53/3246 | 217/18723 | 4.89e-03 | 2.39e-02 | 53 |
| GO:005081714 | Prostate | Tumor | coagulation | 54/3246 | 222/18723 | 4.95e-03 | 2.42e-02 | 54 |
| GO:000759914 | Prostate | Tumor | hemostasis | 53/3246 | 222/18723 | 7.87e-03 | 3.50e-02 | 53 |
| GO:005254728 | Skin | cSCC | regulation of peptidase activity | 177/4864 | 461/18723 | 2.21e-09 | 8.02e-08 | 177 |
| GO:005254828 | Skin | cSCC | regulation of endopeptidase activity | 165/4864 | 432/18723 | 1.18e-08 | 3.63e-07 | 165 |
| GO:004206029 | Skin | cSCC | wound healing | 152/4864 | 422/18723 | 2.66e-06 | 4.26e-05 | 152 |
| GO:004586128 | Skin | cSCC | negative regulation of proteolysis | 128/4864 | 351/18723 | 7.95e-06 | 1.09e-04 | 128 |
| GO:005134627 | Skin | cSCC | negative regulation of hydrolase activity | 130/4864 | 379/18723 | 1.74e-04 | 1.49e-03 | 130 |
| GO:001095125 | Skin | cSCC | negative regulation of endopeptidase activity | 89/4864 | 252/18723 | 6.05e-04 | 4.38e-03 | 89 |
| GO:001046626 | Skin | cSCC | negative regulation of peptidase activity | 91/4864 | 262/18723 | 9.73e-04 | 6.58e-03 | 91 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TFPI | SNV | Missense_Mutation | novel | c.295N>C | p.Glu99Gln | p.E99Q | P10646 | protein_coding | deleterious(0.03) | possibly_damaging(0.851) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TFPI | SNV | Missense_Mutation | rs746176720 | c.637N>A | p.Gly213Ser | p.G213S | P10646 | protein_coding | tolerated(0.39) | benign(0.44) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| TFPI | SNV | Missense_Mutation | rs781414695 | c.889N>A | p.Glu297Lys | p.E297K | P10646 | protein_coding | tolerated(0.16) | possibly_damaging(0.709) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TFPI | SNV | Missense_Mutation | c.238G>A | p.Glu80Lys | p.E80K | P10646 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TFPI | SNV | Missense_Mutation | c.821G>T | p.Arg274Ile | p.R274I | P10646 | protein_coding | deleterious(0) | possibly_damaging(0.641) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TFPI | SNV | Missense_Mutation | c.706N>G | p.Asn236Asp | p.N236D | P10646 | protein_coding | tolerated(0.12) | probably_damaging(0.925) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TFPI | SNV | Missense_Mutation | c.730N>A | p.Pro244Thr | p.P244T | P10646 | protein_coding | deleterious(0.04) | possibly_damaging(0.651) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TFPI | SNV | Missense_Mutation | rs568113767 | c.173N>T | p.Ala58Val | p.A58V | P10646 | protein_coding | tolerated(0.11) | benign(0.101) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| TFPI | insertion | Frame_Shift_Ins | novel | c.755_756insG | p.Asn253LysfsTer2 | p.N253Kfs*2 | P10646 | protein_coding | TCGA-DM-A1D4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| TFPI | SNV | Missense_Mutation | novel | c.419N>T | p.Arg140Met | p.R140M | P10646 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | PI-88 | MUPARFOSTAT | 11292191 | |
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | CHONDROITIN SULFATE | 10959709 | ||
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | AZITHROMYCIN | AZITHROMYCIN | 16113783 | |
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | HEPARIN | HEPARIN | 11150580 | |
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | NN-7415 | |||
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | LOVASTATIN | LOVASTATIN | 7600119 | |
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | CREMOPHOR | 9352228 | ||
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | ATORVASTATIN | ATORVASTATIN | 15792677 | |
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | FULVESTRANT | FULVESTRANT | 17029634 | |
| 7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | CHONDROITIN | 7974391 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |